study aims to characterize the distribution, diversity, and patterns of HCV genotypes in MENA by (1) estimating the country-specific pooled mean proportions of HCV genotypes; (2) assessing the country-specific genotype diversity; and (3) estimating the country-specific number of chronically infected individuals by genotype. This study was conducted under the umbrella of the MENA HCV Epidemiology Synthesis Project, an on-going effort to characterize HCV epidemiology and inform key public health research, policy and programming priorities in MENA. [12] [13] [14] [15] [16] [17] [18] [19] [20] 2 | MATERIALS AND METHODS
| Data sources
The source of data for our study was the MENA HCV Epidemiology Synthesis Project database, a comprehensive database of HCV epidemiological measures. [12] [13] [14] [15] [16] [17] [18] [19] [20] The database consists of several sub-databases such as an HCV genotype frequency sub-database Synthesis Project database was populated through a series of systematic reviews for HCV infection across MENA. [12] [13] [14] [15] [16] [17] [18] [19] [20] The reviews were informed by Cochrane Collaboration handbook 21 and reported their findings using the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. 22 Data sources for these reviews included peer-reviewed publications identified through international scientific databases (PubMed and Embase), regional and country-level scientific databases (World Health
Organization [WHO] Index Medicus for the Eastern Mediterranean
Region, the Iraqi Academic Scientific Journals' database, Iran's Scientific Information Database, among others), MENA HIV/AIDS Epidemiology Synthesis Project database, 23, 24 abstract archives of non-indexed international conferences, and gray literature comprised of public health reports and routine data reporting. Broad search criteria were used combining medical index terms exploded to cover all subheadings and free text terms for HCV and country names, to ensure inclusiveness. No language restrictions were used as non-English articles were extracted by native speakers. Screening of articles was restricted to those published after 1989, the year in which HCV was first identified. 25, 26 Our definition of MENA included 24 countries: Afghanistan, 
| Meta-analyses of genotype proportions
DerSimonian-Laird random-effects meta-analyses with inverse variance weighting 27 were performed to estimate the country-specific pooled mean proportion for each HCV genotype and the corresponding 95% confidence interval (CI). The variance was stabilized using the FreemanTukey type arcsine square-root transformation. 28 Cochran's Q test was conducted to assess heterogeneity in effect size; a P-value <0.1 was considered significant. 27, 29 The I 2 was calculated to assess the proportion of between-study variation in effect size that is due to true differences between studies rather than chance. 27 The metaanalyses were performed when at least three measures were available for each pooled category. 
| Genotypes 5, 6, and 7
Genotype 5 was neither dominant nor common in any MENA country.
It was limited in Syria at 7.6% (95%CI: 0.0-23.0), but otherwise was not observed, or was observed at extremely low levels, in the remaining MENA countries. For the whole MENA sample, the pooled mean proportion for Genotype 5 was 0.0% (95%CI: 0.0-0.0).
Genotype 6 was not observed or was observed at extremely low levels in all countries, leading to a pooled mean proportion of 0.0% (95%CI: 0.0-0.0) for the whole MENA sample. Genotype 7 was not observed in any country.
| Genotype diversity
Supplementary Table S2 lists the estimated genotype diversity by country as assessed using Shannon Diversity Index (H). Weighted by population size in each country, the highest proportion of chronically infected individuals was that of genotype 3 (41.9%), followed by genotype 4 (41.0%), genotype 1 (14.2%), genotype 2 (2.9%), genotype 5 (0.1%), and genotype 6 (0.0%).
| Number of HCV chronically infected individuals by genotype

| DISCUSSION
We presented a comprehensive characterization of HCV genotype distribution, diversity, and patterns in MENA. We found that the distribution varied from one country to another, with evidence for subregionalization patterns for specific genotypes. Most chronically infected individuals were infected with genotypes 3 or 4, with nearly equal contributions for each at just over 40%. However, these large contributions merely reflected the dominance of these genotypes in Pakistan (genotype 3) and Egypt (genotype 4), by far the largest two HCV epidemics in MENA. Over 75% of MENA's chronically infected individuals are found in these two countries. 33 While genotype 1 was present throughout the region, and was dominant or common in most countries, it had limited presence in both Egypt and Pakistan, and hence its contribution did not exceed 15%.
Genotypes 2, 5, 6, and 7 did not have significant presence in MENA.
While there was considerable genotype diversity in most countries, there was limited diversity in both Egypt and Pakistan. These findings inform the current expansion of DAA treatment programs in MENA, and provide insights about the transmission pathways of this infection.
FIGURE 1
The country-specific distribution of hepatitis C virus (HCV) genotypes across the Middle East and North Africa (MENA) region. Legend: ‡ Countries in which less than three studies were available. Djibouti, Mauritania, Somalia, Sudan, and Yemen were excluded either due to no studies available or small sample size The distribution of HCV genotypes in MENA appears to reflect three sub-regional patterns ( Figure 2 ). The first is that of dominance of genotype 3, a pattern found in Pakistan and Afghanistan, and to some extent in Iran (Figures 1 and 2 ). This pattern is possibly explained by the fact that these are neighboring countries with mass cross-border population movements and porous borders.
35,36
The second pattern is that of dominance, or large presence, of genotype 4 which is found in Egypt, its neighboring countries, and/or in countries that host or have hosted large migrant labor populations from Egypt 15, 18, 37 (Figures 1 and 2 ). This pattern is possibly explained by the unique nature of the Egyptian epidemic, 12, 38 which has led to circulation of genotype 4 through population movement to countries with strong links to Egypt. Countries that have imported large Egyptian labor populations included Iraq, Jordan, Kuwait, Libya, Oman, Qatar, Saudi Arabia, and UAE. 39 It bears notice, nonetheless, that the circulation of this genotype out of Egypt does not seem to have impacted significantly HCV prevalence in these countries. HCV prevalence in these countries is much lower than that in Egypt. 12, 13, 15, 18, 38 The third pattern is that of dominance, or large presence, of genotype 1 which is found in the Maghreb sub-region of MENA (Algeria, Morocco, Tunisia, and to some extent Libya), part of the Arabian Gulf sub-region (Oman and UAE), Iran, and to some extent Lebanon ( Figure 2 ). This pattern is similar to the most common global pattern, 7, 9 and may reflect population movement links with countries outside MENA, such as the Maghreb sub-region migration links with
Western and Southern Europe. 40, 41 There are also large and diverse expatriate populations in the Arabian Gulf sub-region, and this may have contributed to this pattern. 18 While these three patterns are largely distinct, some overlap is seen such as for countries that border different patterns-Iran and Libya provide two examples (Figures 1 and 2) . The Arabian Gulf subregion also exhibits such overlap with its diverse migrant-population composition-as reflected in the high genotype diversity for the majority of Arabian Gulf countries (Figure 3 , Supplementary Table S2) .
Lastly, genotype 2 was mainly present in the Maghreb sub-region, possibly because of geographic proximity and population links with West Africa where this genotype is most frequent. 7, 42, 43 Genotype diversity varied across the region. The variability in genotype diversity is probably attributable to factors including, among others, specific historical events, such as the case for Egypt, 12, 38, 44 how HCV was introduced to each country, such as through migrant population movements, 40, 41 and importation of blood products (mostly from Western countries) before the onset of HCV blood screening, 24, 45 Genotype diversity appears also to be influenced by the type of drivers of HCV transmission in each country, such as the role of PWID and association with genotype 3. Injecting drug use is a major challenge in MENA, 48 ,49 but we found a small number of genotype studies among PWID. Available data suggests that the genotypes circulating among PWID in a given country, tend to be similar to those circulating in the wider population in this country (Supplementary Table S1 ). We are thus unable to see whether there are associations between specific genotypes and injecting drug use, such as the genotype 3 link seen in the global literature. 7, 50, 51 As suggested by recent studies, however, there seems to be a shift toward genotype 3 in Iran. 46, 47 This is particularly among young patients, and is apparently linked to injecting drug use increasingly becoming the main route of HCV transmission. 46, 47 Our study has several limitations. We did not find HCV genotype studies for four MENA countries, and there were too few studies to conduct meta-analyses for another five countries. The number of studies also varied by country, and sample size of genotyped individuals was small for a number of studies. Studies may have also sampled populations from specific geographic areas within a given country, or select sub-populations. We did not assess secular trends in genotype distribution, such as using meta-regressions, as such analyses are challenged by the heterogeneity in available data and by the fact that genotype diversity is very low in the two countries that contribute most chronic infections in this region (namely, Egypt and Pakistan; Table 2 ). Accordingly, available genotype data may not have Djibouti, Mauritania, Somalia, Sudan, and Yemen were excluded either due to no studies available or small sample size.
| 139 captured the diversity and true distribution of genotypes in the wider population of each country.
Key strengths of our study are the systematic and comprehensive searches that yielded our input data, and the fact that we synthesized and analyzed these data using state of the art quantitative methods. In addition to international databases, we identified a volume of data through regional and national databases, and included non-English articles, public health reports, and routine data reporting. We have therefore identified much more data than is present in existing global or regional studies of HCV genotypes, 7, 9, 52 and presented a detailed picture of HCV genotypes and their patterns and diversity in MENA.
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